CytoSorbents regained Nasdaq compliance with the $1 minimum bid price rule, based on 10 consecutive sessions ending Sept. 21, 2026.
Nasdaq closed the bid-price deficiency matter following notification received Sept. 22, 2026.
The company still faces a separate Nasdaq Capital Market listing requirement tied to minimum market value of listed securities, with a Dec. 28, 2026 deadline.
CTSO•
